MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
ARVN Arvinas
- 18.480
- +0.650+3.65%
Close Dec 20 16:00 ET
- 18.480
- 0.0000.00%
Post 16:13 ET
1.27BMarket Cap-3.86P/E (TTM)
18.700High17.530Low1.76MVolume17.620Open17.830Pre Close31.97MTurnover3.09%Turnover RatioLossP/E (Static)68.71MShares53.08052wk High2.17P/B1.06BFloat Cap17.37052wk Low--Dividend TTM57.18MShs Float108.465Historical High--Div YieldTTM6.56%Amplitude10.190Historical Low18.126Avg Price1Lot Size
About Arvinas Company
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
Company Profile
SymbolARVN
Company NameArvinas
Listing DateSep 27, 2018
Issue Price16.00
Founded2013
CEODr. John G. Houston, PhD
MarketNASDAQ
Employees445
Fiscal Year Ends12-31
Address5 Science Park,395 Winchester Avenue
CityNew Haven
ProvinceConnecticut
CountryUnited States of America
Zip Code06511
Phone1-203-535-1456
Websitehttp://www.arvinas.com
Company Executives
- Name
- Position
- Salary
- Dr. John G. Houston, PhD
- Chairman of the Board, President and Chief Executive Officer
- 7.63M
- Andrew Saik
- Chief Financial Officer and Treasurer
- --
- Dr. Angela Cacace, PhD
- Chief Scientific Officer
- --
- David Loomis
- Vice President and Chief Accounting Officer
- --
- Randy Teel, PhD
- Chief Business Officer
- --
- Dr. Noah Berkowitz, M.D.
- Chief Medical Officer
- --
- Dr. Ian Taylor, PhD
- President, Research and Development
- 2.73M
- Everett V. Cunningham
- Independent Director
- 350.00K
- Leslie V. Norwalk, Esq.
- Independent Director
- 350.00K
- Edward Kennedy, Jr
- Independent Director
- 345.41K
- Dr. Sunil Agarwal, M.D.
- Independent Director
- 784.74K
- Dr. Laurie Smaldone Alsup, M.D.
- Independent Director
- 430.30K
- John Douglas Young
- Independent Director
- 422.49K
- Linda C. Bain
- Independent Director
- 370.00K
- Dr. Briggs W. Morrison, M.D.
- Lead Independent Director
- 383.54K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.